Do you hold Tresiba (insulin degludec) in a diabetic patient who is not eating?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 30, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Do Not Hold Tresiba (Insulin Degludec) When Patient Is Not Eating

Basal insulin like Tresiba should be continued at a reduced dose—not held completely—in patients who are not eating. This is essential to prevent diabetic ketoacidosis in type 1 diabetes and to suppress hepatic glucose production in type 2 diabetes 1.

Why Basal Insulin Must Be Continued

The fundamental principle is that basal insulin addresses background glucose control independent of meals. During illness or periods of poor oral intake, insulin requirements may be altered, but complete discontinuation of basal insulin can lead to severe hyperglycemia and metabolic derangement 2, 1.

  • For type 1 diabetes patients: Basal insulin is absolutely required even when not eating to prevent diabetic ketoacidosis 1
  • For type 2 diabetes patients: Basal insulin continues to suppress hepatic glucose production between meals and control fasting glucose 1
  • The American Diabetes Association explicitly states that during illness, it is important that insulin be continued even if the patient is unable to eat or is vomiting 2

Dose Reduction Strategy

Rather than holding Tresiba completely, reduce the dose based on the patient's risk profile:

For Hospitalized Patients Not Eating:

  • Reduce total daily insulin to 0.1-0.15 units/kg/day given primarily as basal insulin 1
  • For high-risk patients (elderly >65 years, renal failure, poor oral intake): use 0.1-0.25 units/kg/day 3, 1
  • If patient was on high-dose home insulin (≥0.6 units/kg/day), reduce total daily dose by 20% upon hospitalization 3, 1

Monitoring Requirements:

  • Check glucose every 4-6 hours for patients not eating (rather than pre-meal testing) 2, 1
  • Use correction doses of rapid-acting insulin only for significant hyperglycemia, typically >180-250 mg/dL 1
  • A simplified correction scale: 2 units for glucose >250 mg/dL and 4 units for glucose >350 mg/dL 1

Critical Pitfall to Avoid

Completely withholding basal insulin when a patient is not eating is a dangerous error that leads to worsening hyperglycemia and potential metabolic crisis 4. The common misconception is that "no food = no insulin," but basal insulin works independently of meals to control background glucose levels 2.

Hypoglycemia Prevention

  • If hypoglycemia occurs, reduce the basal insulin dose by 10-20% immediately 1
  • The risk of hypoglycemia increases significantly in patients with renal impairment, hepatic impairment, elderly patients, and those with unpredictable oral intake 1
  • Monitor closely for hypoglycemia, especially during overnight hours 4

Special Considerations for Tresiba

Tresiba (insulin degludec) has an ultra-long duration of action exceeding 42 hours with a flat, stable glucose-lowering profile 5, 6. This extended action means that even with reduced oral intake, the insulin continues to provide essential basal coverage with lower risk of hypoglycemia compared to other basal insulins 7, 6.

References

Guideline

Managing Insulin Therapy in Patients with Reduced Oral Intake

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Initial Dosing for Lantus (Insulin Glargine) in Patients Requiring Insulin Therapy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Insulin Administration Guidelines for Hospitalized Patients with Hyperglycemia

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.